Scientific Publication

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

A new analysis shows AI platforms can cut hospital costs by $2M annually while reducing ICU stays and ventilation time, transforming critical care.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

A new study reveals adults with IDD are 9x more likely to have anxiety or depression, yet face immense barriers to care. This is a systemic failure.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A newly identified molecule, HOXD13, both fuels melanoma growth and shields it from the immune system, paving the way for a novel combination therapy.

A California charter network's impressive academic gains are forcing a rethink on the effectiveness of non-classroom-based learning for diverse students.

A landmark study of 2.8 million people unpacks the complex causes of food allergies, vindicates vaccines, and offers parents clarity on what they can control.

A new model from an independent researcher proposes a 'pixel size' for spacetime and a mass limit where quantum reality ends, converging with a Nobel laureate.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

New drill results from Emerita's El Cura deposit show significant high-grade metals, boosting a key study and Europe's critical mineral supply chain.

Johnson & Johnson unveils promising data for its next-gen AFib tech while reinforcing the safety of its current platform in a competitive market.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.